businesspress24.com - Cleveland BioLabs Announces Date Change for Second Quarter 2015 Financial Results
 

Cleveland BioLabs Announces Date Change for Second Quarter 2015 Financial Results

ID: 1376160

Corporate Update Call at 10:00 am ET August 12, 2015

(firmenpresse) - BUFFALO, NY -- (Marketwired) -- 07/31/15 -- (NASDAQ: CBLI) today announced that on August 12, 2015, it will report its financial results for the second quarter and six-month period ended June 30, 2015, and will host a conference call at 10:00 a.m. ET.

Interested parties may participate by dialing 877-407-9205 (US) or 201-689-8054 (International), approximately five to ten minutes before the call start time. A live webcast of the conference call will be available on the investor page of the Cleveland BioLabs website at .

A replay of the call will be available starting on August 12, 2015, at 1:00 p.m. ET through August 26, 2015, at 11:59 p.m. ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering conference ID number 13613931. An archived webcast of the conference call will be available for 90 days on the Investors page of the Cleveland BioLabs website at .



Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. The company''s proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company''s most advanced product candidate is entolimod, which is being developed for a biodefense indication and as an immunotherapy for oncology and other indications. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and a joint venture with OJSC Rusnano, Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company''s website at .



Contact:
Rachel Levine
Vice President Investor Relations
Cleveland BioLabs, Inc.
T: (917) 375-2935
Email:






Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  OrganiGram Releases Q3 Financial Results and Provides Operational Update
Io Therapeutics, Inc. Announces Sponsored Research Agreement With the National Multiple Sclerosis Society Fast Forward Program
Bereitgestellt von Benutzer: Marketwired
Datum: 31.07.2015 - 11:00 Uhr
Sprache: Deutsch
News-ID 1376160
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

BUFFALO, NY


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 304 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Cleveland BioLabs Announces Date Change for Second Quarter 2015 Financial Results
"
steht unter der journalistisch-redaktionellen Verantwortung von

Cleveland BioLabs, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Cleveland BioLabs, Inc.



 

Who is online

All members: 10 591
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 122


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.